Diffuse large B-cell lymphoma of Waldeyer's ring has distinct clinicopathologic features: a GELA study.

[en] Background:Diffuse large B-cell lymphomas (DLBCLs) arising in specific extranodal sites have peculiarclinicopathologic features.Patients and methods:We analyzed a cohort of 187 primary Waldeyer’s ring (WR) DLBCLs retrieved from GELAprotocols using anthracyclin-based polychemotherapy.Results:Most patients (92%) had stage I–II disease. A germinal center B-cell-like (GCB) immunophenotype wasobserved in 61%, and BCL2 expression in 55%, of WR DLBCLs.BCL2,BCL6,IRF4andMYCbreakpoints wereobserved in, respectively, 3 of 42 (7%), 9 of 36 (25%), 2 of 26 (8%) and 4 of 40 (10%) contributive cases. A variablefollicular pattern was evidenced in 30 of 68 (44%) large biopsy specimens. The 5-year progression-free survival (PFS)†These authors contributed equally to this work.*Correspondence to: Professor Dr L. de Leval, Department of Laboratories, Institute ofPathology, CHUV, rue du Bugnon 25, 1011 Lausanne, Switzerland. Tel: +41-31-314-71-94; Fax: +41-31-314-72-05; E-mail: laurence.deleval@chuv.chAnnals of Oncologyoriginal articles© The Author 2012. Published by Oxford University Press on behalf of the European Society for Medical Oncology.All rights reserved. For permissions, please email: journals.permissions@oup.com.Downloaded from https://academic.oup.com/annonc/article-abstract/23/12/3143/175938 by University of Liege user on 24 October 2019 and the overall survival (OS) of 153 WR DLBCL patients with survival information were 69.5% and 77.8%, respectively.The GCB immunophenotype correlated with a better OS (P= 0.0015), while BCL2 expression predicted a worse OS(P= 0.037), an effect overcome by the GCB/non-GCB classification. Compared with matched nodal DLBCLs, WRDLBCLs with no age-adjusted international prognostic index factor disclosed a better 5-year PFS rate (77.5% versus70.7%;P= 0.03).Conclusions:WR DLBCLs display distinct clinicopathologic features compared with conventional DLBCLs, with usuallocalized-stage disease, common follicular features and a high frequency of GCB immunophenotype contrasting with alow rate ofBCL2rearrangements. In addition, they seem to be associated with a better outcome than their nodalcounterpart

Disciplines :

Hematology

Author, co-author :

de Leval, Laurence ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Département des sciences biomédicales et précliniques

BONNET, Christophe ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service d'hématologie clinique

Copie-Bergman, C.

SEIDEL, Laurence ; Centre Hospitalier Universitaire de Liège - CHU > Département de gestion des systèmes d'informations (GSI) > Secteur d'appui à la recherche clinique et biostatistique

Baia, M.

Brière, J.

Molina, TJ.

Fabiani, B.

Petrella, T.

Bosq, J.

More authors (6 more)

Language :

English

Title :

Diffuse large B-cell lymphoma of Waldeyer's ring has distinct clinicopathologic features: a GELA study.

Publication date :

2012

Journal title :

Annals of Oncology

ISSN :

0923-7534

eISSN :

1569-8041

Publisher :

Oxford University Press, United Kingdom

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 24 November 2019

Statistics

Number of views

82 (3 by ULiège)

Number of downloads

51 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

d'Amore F, Christensen BE, Brincker H et al. Clinicopathological features and prognostic factors in extranodal non-Hodgkin lymphomas. Danish LYFO Study Group. Eur J Cancer 1991; 27: 1201-1208.
Swerdlow S, Campo E, Harris N et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press 2008.
Deckert M, Engert A, Bruck W et al. Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphoma. Leukemia 2011; 25: 1797-1807.
Steidl C, Gascoyne RD. The molecular pathogenesis of primary mediastinal large B-cell lymphoma. Blood 2011; 118: 2659-2669.
Vega F, Lin P, Medeiros LJ. Extranodal lymphomas of the head and neck. Ann Diagn Pathol 2005; 9: 340-350.
Reyes F, Lepage E, Ganem G et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med 2005; 352: 1197-1205.
Gospodarowicz MK, Sutcliffe SB, Brown TC et al. Patterns of disease in localized extranodal lymphomas. J Clin Oncol 1987; 5: 875-880.
Zucca E, Roggero E, Bertoni F et al. Primary extranodal non-Hodgkin's lymphomas. Part 2: Head and neck, central nervous system and other less common sites. Ann Oncol 1999; 10: 1023-1033.
Krol AD, Le Cessie S, Snijder S et al. Waldeyer's ring lymphomas: a clinical study from the Comprehensive Cancer Center West population based NHL registry. Leuk Lymphoma 2001; 42: 1005-1013.
Ree HJ, Kikuchi M, Lee SS et al. Focal follicular features in tonsillar diffuse large B-cell lymphomas: follicular lymphoma with diffuse areas or follicular colonization. Hum Pathol 2002; 33: 732-740.
Salaverria I, Philipp C, Oschlies I et al. Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adults. Blood 2011; 118: 139-147.
Menarguez J, Mollejo M, Carion R et al. Waldeyer ring lymphomas. A clinicopathlogical study of 79 cases. Histopathology 1994; 24: 13-22.
Lopez-Guillermo A, Colomo L, Jimenez M et al. Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin. J Clin Oncol 2005; 23: 2797-2804.
Qi S, Li Y, Wang H et al. Diffuse large B-cell lymphoma: clinical characterization and prognosis of Waldeyer ring versus lymph node presentation. Cancer 2009; 115: 4980-4989.
Shimm D, Dosoretz D, Harris NL et al. Radiation therapy of Waldeyer's ring lymphoma. Cancer 1984; 54: 426-431.
Gurkaynak M, Cengiz M, Akyurek S et al. Waldeyer's ring lymphomas: treatment results and prognostic factors. Am J Clin Oncol 2003; 26: 437-440.
Ezzat AA, Ibrahim EM, El Weshi AN et al. Localized non-Hodgkin's lymphoma of Waldeyer's ring: clinical features, management, and prognosis of 130 adult patients. Head Neck 2001; 23: 547-558.
Mohammadianpanah M, Omidvai S, Mosalei A, Ahmadloo N. Treatment results of tonsillar lymphoma: a 10-year experience. Ann Hematol 2005; 84: 223-226.
Qin Y, Shi YK, He XH et al. Clinical features of 89 patients with primary non-Hodgkin's lymphoma of the tonsil. Chinese J Cancer 2006; 25: 481-485.
Laskar S, Bahl G, Muckaden MA et al. Primary diffuse large B-cell lymphoma of the tonsil: is a higher radiotherapy dose required? Cancer 2007; 110: 816-823.
Gisselbrecht C, Lepage E, Molina T et al. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol 2002; 20: 2472-2479.
Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
Tilly H, Lepage E, Coiffier B et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 2003; 102: 4284-4289.
Bonnet C, Fillet G, Mounier N et al. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2007; 25: 787-792.
Morel P, Munck B, Coiffier B. A new high dose CHOP regimen followed by an intensive consolidation in patients (pts) aged ≤60 years with aggressive lymphoma (NHL) presenting with only one adverse prognostic factor of the international prognostic index (IPI). An interim analysis of the LNH93-2 protocol on 433 pts. [Abstract]. Blood 2007; 90: 587a.
Hermine O, Haioun C, Lepage E et al. Prognostic significance of bcl-2 protein expression in aggressive non- Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 1996; 87: 265-272.
Hans CP, Weisenburger DD, Greiner TC et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-282.
Copie-Bergman C, Gaulard P, Leroy K et al. Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study. J Clin Oncol 2009; 27: 5573-5579.
Harabuchi Y, Tsubota H, Ohguro S et al. Prognostic factors and treatment outcome in non-Hodgkin's lymphoma of Waldeyer's ring. Acta Oncol 1997; 36: 413-420.
Colomo L, Lopez-Guillermo A, Perales M et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 2003; 101: 78-84.
Berglund M, Thunberg U, Amini RM et al. Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis. Mod Pathol 2005; 18: 1113-1120.
Ott G, Ziepert M, Klapper W et al. Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. Blood 2010; 116: 4916-4925.
Huang JZ, Sanger WG, Greiner TC et al. The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood 2002; 99: 2285-2290.
Bastard C, Deweindt C, Kerckaert JP et al. LAZ3 rearrangements in non-Hodgkin's lymphoma: correlation with histology, immunophenotype, karyotype, and clinical outcome in 217 patients. Blood 1994; 83: 2423-2427.
Ott G, Katzenberger T, Lohr A et al. Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade Blood 2002; 99: 3806-3812.
Bosga-Bouwer AG, van Imhoff GW, Boonstra R et al. Follicular lymphoma grade 3B includes 3 cytogenetically defined subgroups with primary t(14;18), 3q27, or other translocations: t(14;18) and 3q27 are mutually exclusive. Blood 2003; 101: 1149-1154.
Katzenberger T, Ott G, Klein T et al. Cytogenetic alterations affecting BCL6 are predominantly found in follicular lymphomas grade 3B with a diffuse large B-cell component. Am J Pathol 2004; 165: 481-490.
Bosga-Bouwer AG, van den Berg A, Haralambieva E et al. Molecular, cytogenetic, and immunophenotypic characterization of follicular lymphoma grade 3B; a separate entity or part of the spectrum of diffuse large B-cell lymphoma or follicular lymphoma? Hum Pathol 2006; 37: 528-533.
Lorsbach RB, Shay-Seymore D, Moore J et al. Clinicopathologic analysis of follicular lymphoma occurring in children. Blood 2002; 99: 1959-1964.
Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. [In process citation]. Nature 2000; 403: 503-511.
Shipp MA, Ross KN, Tamayo P et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002; 8: 68-74.
Rosenwald A, Wright G, Chan WC et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937-1947.
Lossos IS, Czerwinski DK, Alizadeh AA et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 2004; 350: 1828-1837.
Rimsza LM, Leblanc ML, Unger JM et al. Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. Blood 2008; 112: 3425-3433.
Malumbres R, Chen J, Tibshirani R et al. Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Blood 2008; 111: 5509-5514.
Jais JP, Haioun C, Molina TJ et al. The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab. Leukemia 2008; 22: 1917-1924.
Chang CC, McClintock S, Cleveland RP et al. Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol 2004; 28: 464-470.
van Imhoff GW, Boerma EJ, van der Holt B et al. Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 4135-4142.
Zinzani PL, Dirnhofer S, Sabattini E et al. Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays. Haematologica 2005; 90: 341-347.
Gascoyne RD, Adomat SA, Krajewski S et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 1997; 90: 244-251.
Barrans SL, Carter I, Owen RG et al. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 2002; 99: 1136-1143.
Mounier N, Briere J, Gisselbrecht C et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003; 101: 4279-4284.
Iqbal J, Neppalli VT, Wright G et al. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 961-968.